

# CITATION REPORT

List of articles citing

**PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer**

**DOI: 10.1016/j.pharmthera.2014.10.003**

**Pharmacology & Therapeutics, 2015, 147, 12-21.**

**Source:** <https://exaly.com/paper-pdf/62797672/citation-report.pdf>

**Version:** 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
169	Chronic Inhibition of PDE5 Limits Pro-Inflammatory Monocyte-Macrophage Polarization in Streptozotocin-Induced Diabetic Mice. <i>PLoS ONE</i> , <b>2015</b> , 10, e0126580	3.7	34
168	Phosphodiesterase-5 Inhibitors: Action on the Signaling Pathways of Neuroinflammation, Neurodegeneration, and Cognition. <b>2015</b> , 2015, 940207		55
167	Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs. <b>2015</b> , 2015, 138148		32
166	Duchenne muscular dystrophy: clinical trials and emerging tribulations. <b>2015</b> , 28, 542-6		21
165	Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension. <b>2015</b> , 47, e175		38
164	Erectile dysfunction and its management in patients with diabetes mellitus. <b>2015</b> , 16, 213		19
163	Overview of potential molecular targets for hydrogen sulfide: A new strategy for treating erectile dysfunction. <b>2015</b> , 50, 65-78		12
162	Novel Radioligands for Cyclic Nucleotide Phosphodiesterase Imaging with Positron Emission Tomography: An Update on Developments Since 2012. <b>2016</b> , 21,		15
161	A Combination of Leucine, Metformin, and Sildenafil Treats Nonalcoholic Fatty Liver Disease and Steatohepatitis in Mice. <b>2016</b> , 2016, 9185987		17
160	Novel Perspectives in Redox Biology and Pathophysiology of Failing Myocytes: Modulation of the Intramyocardial Redox Milieu for Therapeutic Interventions-A Review Article from the Working Group of Cardiac Cell Biology, Italian Society of Cardiology. <b>2016</b> , 2016, 6353469		8
159	The CXCL10/CXCR3 Axis and Cardiac Inflammation: Implications for Immunotherapy to Treat Infectious and Noninfectious Diseases of the Heart. <b>2016</b> , 2016, 4396368		33
158	PDE5 Inhibitors-Loaded Nanovesicles: Physico-Chemical Properties and In Vitro Antiproliferative Activity. <b>2016</b> , 6,		16
157	Modulation of Autophagy by Sorafenib: Effects on Treatment Response. <i>Frontiers in Pharmacology</i> , <b>2016</b> , 7, 151	5.6	69
156	Downregulation of GSTK1 Is a Common Mechanism Underlying Hypertrophic Cardiomyopathy. <i>Frontiers in Pharmacology</i> , <b>2016</b> , 7, 162	5.6	29
155	Coadjuvants in the Diabetic Complications: Nutraceuticals and Drugs with Pleiotropic Effects. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17,	6.3	23
154	Sildenafil (Viagra) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95. <i>Oncotarget</i> , <b>2016</b> , 7, 4399-413	3.3	29
153	Protective approaches against myocardial ischemia reperfusion injury. <b>2016</b> , 12, 3823-3829		26

152	Cyclic nucleotide phosphodiesterases in heart and vessels: A therapeutic perspective. <b>2016</b> , 109, 431-43	73
151	The Role of PDE5 Inhibitors and the NO/cGMP Pathway in Cancer. <b>2016</b> , 4, 74-84	26
150	Melanoma, Viagra, and PDE5 Inhibitors: Proliferation and Metastasis. <b>2016</b> , 2, 163-165	4
149	Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs. <b>2016</b> , 22, 449-58	42
148	[Cyclic nucleotide phosphodiesterases: role in the heart and therapeutic perspectives]. <b>2016</b> , 210, 127-138	1
147	Rapid and sensitive liquid chromatography with tandem mass spectrometry method for the simultaneous quantification of yonkenafil and its major metabolites in rat plasma. <b>2016</b> , 39, 3700-3708	1
146	VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection. <b>2016</b> , 113, 13144-13149	72
145	Preventing antiproliferative drug-related cardiomyopathy: old and new therapeutic strategies. <b>2016</b> , 17 Suppl 1, S64-75	18
144	Novel risk factors for acute coronary syndromes and emerging therapies. <b>2016</b> , 220, 815-24	7
143	Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease. <b>2016</b> , 15, 620-638	175
142	Sildenafil Potentiates a cGMP-Dependent Pathway to Promote Melanoma Growth. <b>2016</b> , 14, 2599-610	49
141	The vasodilatory effect of sulfur dioxide via SGC/cGMP/PKG pathway in association with sulfhydryl-dependent dimerization. <b>2016</b> , 310, R1073-80	18
140	Concomitant Phosphodiesterase 5 Inhibition Enhances Myocardial Protection by Inhaled Nitric Oxide in Ischemia-Reperfusion Injury. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2016</b> , 356, 284-92	4-7 13
139	Doxorubicin induced heart failure: Phenotype and molecular mechanisms. <b>2016</b> , 10, 17-24	155
138	Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?. <b>2016</b> , 39, 131-42	18
137	Non-Sexual Implications of Phosphodiesterase Type 5 Inhibitors. <b>2017</b> , 5, 170-199	11
136	Hydrogen sulfide, an enhancer of vascular nitric oxide signaling: mechanisms and implications. <b>2017</b> , 312, C3-C15	98
135	PDE5 Inhibitor Tadalafil and Hydroxychloroquine Cotreatment Provides Synergistic Protection against Type 2 Diabetes and Myocardial Infarction in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2017</b> , 361, 29-38	4-7 5

134	Inhibition of PDE5A1 guanosine cyclic monophosphate (cGMP) hydrolysing activity by sildenafil analogues that inhibit cellular cGMP efflux. <i>Journal of Pharmacy and Pharmacology</i> , <b>2017</b> , 69, 675-683	4.8	6
133	Erectile dysfunction and cardiovascular disease: a suitable case for treatment and prevention?. <b>2017</b> , 103, 1231-1232		1
132	ATR-FTIR characterization of generic brand-named and counterfeit sildenafil- and tadalafil-based tablets found on the Brazilian market. <b>2017</b> , 57, 283-295		20
131	Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes. <b>2017</b> , 19, 326-336		52
130	The cardioprotective effect of sildenafil is mediated by the activation of malate dehydrogenase and an increase in the malate-aspartate shuttle in cardiomyocytes. <b>2017</b> , 127, 60-70		8
129	Effects of cyclic nucleotide phosphodiesterases (PDEs) on mitochondrial skeletal muscle functions. <b>2017</b> , 74, 1883-1893		14
128	Chronic treatment with novel nanoformulated micelles of rapamycin, Rapatar, protects diabetic heart against ischaemia/reperfusion injury. <i>British Journal of Pharmacology</i> , <b>2017</b> , 174, 4771-4784	8.6	13
127	Cyclic guanosine monophosphate modulates accumulation of phosphodiesterase 5 inhibitors in human platelets. <b>2017</b> , 145, 54-63		6
126	A comprehensive review on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases. <i>Biomedicine and Pharmacotherapy</i> , <b>2017</b> , 94, 541-556	7.5	25
125	Transcription Factor CREM Mediates High Glucose Response in Cardiomyocytes and in a Male Mouse Model of Prolonged Hyperglycemia. <b>2017</b> , 158, 2391-2405		14
124	Effects of chronic administration of the phosphodiesterase inhibitor vardenafil on serum levels of adrenal and testicular steroids in men with type 2 diabetes mellitus. <b>2017</b> , 56, 426-437		3
123	Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors. <b>2017</b> , 13, 183-192		19
122	Effect of sildenafil on human aromatase activity: From in vitro structural analysis to catalysis and inhibition in cells. <b>2017</b> , 165, 438-447		8
121	Icariside II Effectively Reduces Spatial Learning and Memory Impairments in Alzheimer $\beta$ Disease Model Mice Targeting Beta-Amyloid Production. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 106	5.6	28
120	From rapalogs to anti-aging formula. <i>Oncotarget</i> , <b>2017</b> , 8, 35492-35507	3.3	61
119	PDE5 Overexpression in Well-Differentiated Thyroid Carcinomas Is Associated with Lymph Node Metastasis. <b>2017</b> , 2017, 6243932		0
118	PDE5 Inhibitors Offer Novel Mechanisms in Combination and Solo Cancer Therapy. <b>2017</b> , 13,		2
117	Inhibition of Phosphodiesterase 5 and Increasing the Level of Cyclic Guanosine 3',5'-cyclic monophosphate by Hydroalcoholic C. Koch Extract in Human Breast Cancer Cell Lines MCF-7 and MDA-Mb-468. <b>2017</b> , 11, 1178223417690178		6

116	Phosphodiesterase type 5 and cancers: progress and challenges. <i>Oncotarget</i> , <b>2017</b> , 8, 99179-99202	3.3	28
115	Protective role of melatonin in cardiac ischemia-reperfusion injury: From pathogenesis to targeted therapy. <b>2018</b> , 64, e12471		158
114	PDE5 inhibition eliminates cancer stem cells via induction of PKA signaling. <b>2018</b> , 9, 192		18
113	Sildenafil normalizes MALAT1 level in diabetic cardiomyopathy. <b>2018</b> , 62, 259-262		15
112	Effects of the NO/soluble guanylate cyclase/cGMP system on the functions of human platelets. <b>2018</b> , 76, 71-80		49
111	Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure. <i>British Journal of Pharmacology</i> , <b>2018</b> , 175, 223-231	8.6	21
110	Phosphodiesterase-5 inhibition preserves exercise-onset vasodilator kinetics when NOS activity is reduced. <b>2018</b> , 124, 276-282		5
109	PDE5 inhibitor protects the mitochondrial function of hypoxic myocardial cells. <b>2019</b> , 17, 199-204		7
108	The anti-inflammatory and anti-fibrotic effects of tadalafil in thioacetamide-induced liver fibrosis in rats. <b>2018</b> , 96, 1308-1317		20
107	Icariside II attenuates cardiac remodeling via AMPK $\alpha$ /mTORC1 in vivo and in vitro. <b>2018</b> , 138, 38-45		4
106	Molecular and pathophysiological links between heart failure with preserved ejection fraction and type 2 diabetes mellitus. <b>2018</b> , 20, 1649-1652		6
105	Acute Enhancement of Cardiac Function by Phosphodiesterase Type 1 Inhibition. <b>2018</b> , 138, 1974-1987		39
104	cGMP at the centre of attention: emerging strategies for activating the cardioprotective PKG pathway. <b>2018</b> , 113, 24		42
103	Insights into the pharmaceuticals and mechanisms of neurological orphan diseases: Current Status and future expectations. <b>2018</b> , 169, 135-157		5
102	Connexins and Nitric Oxide Inside and Outside Mitochondria: Significance for Cardiac Protection and Adaptation. <b>2018</b> , 9, 479		8
101	Skeletal Muscle Metabolism in Duchenne and Becker Muscular Dystrophy-Implications for Therapies. <b>2018</b> , 10,		25
100	Roles of PDE1 in Pathological Cardiac Remodeling and Dysfunction. <b>2018</b> , 5,		9
99	Cardiomyopathy Associated with Diabetes: The Central Role of the Cardiomyocyte. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	40

98	Biphasic Effect of Sildenafil on Energy Sensing is Mediated by Phosphodiesterases 2 and 3 in Adipocytes and Hepatocytes. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	3
97	Radiosynthesis of carbon-11 labeled PDE5 inhibitors as new potential PET radiotracers for imaging of Alzheimer's disease. <b>2019</b> , 154, 108873		5
96	Phosphodiesterase inhibitors say NO to Alzheimer's disease. <b>2019</b> , 134, 110822		33
95	Targeting cyclic nucleotide phosphodiesterase 5 (PDE5) in brain: Toward the development of a PET radioligand labeled with fluorine-18. <b>2019</b> , 86, 346-362		8
94	Chronic administration of sildenafil improves endothelial function in spontaneously hypertensive rats by decreasing COX-2 expression and oxidative stress. <b>2019</b> , 225, 29-38		9
93	PDE5A Suppresses Proteasome Activity Leading to Insulin Resistance in C2C12 Myotubes. <b>2019</b> , 2019, 3054820		4
92	Nitrogen Monoxide (Nitric Oxide): Bioinorganic Chemistry. <b>2019</b> , 1-20		
91	Needs and Expectations of Patients with Erectile Dysfunction: An Update on Pharmacological Innovations in Phosphodiesterase Type 5 Inhibition with Focus on Sildenafil. <b>2019</b> , 7, 1-10		13
90	Randomized Controlled Trial of a Leucine-Metformin-Sildenafil Combination (NS-0200) on Weight and Metabolic Parameters. <b>2019</b> , 27, 59-67		13
89	The phosphodiesterase 5 inhibitor sildenafil decreases the proinflammatory chemokine IL-8 in diabetic cardiomyopathy: in vivo and in vitro evidence. <b>2019</b> , 42, 715-725		19
88	Phosphodiesterase Type 5 (PDE5) Inhibitors Sensitize Topoisomerase II Inhibitors in Killing Prostate Cancer Through PDE5-Independent Impairment of HR and NHEJ DNA Repair Systems. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 681	5.3	11
87	Design, synthesis and evaluation of N,N-diaminoquinazoline based inhibitors of phosphodiesterase type 5. <b>2019</b> , 29, 267-270		6
86	Upregulation of SERT and ADORA1 in broilers with acute right ventricular failure. <b>2019</b> , 125, 397-400		2
85	The erectile dysfunction as a marker of cardiovascular disease: a review. <b>2020</b> , 75, 286-292		18
84	Organic Isothiocyanates as Hydrogen Sulfide Donors. <b>2020</b> , 32, 110-144		30
83	Sildenafil triggers tumor lethality through altered expression of HSP90 and degradation of PKD2. <b>2020</b> , 41, 1421-1431		3
82	Genes of the cGMP-PKG-Ca signaling pathway are alternatively spliced in cardiomyopathy: Role of RBFOX2. <b>2020</b> , 1866, 165620		4
81	PDE1 or PDE5 inhibition augments NO-dependent hypoxic constriction of porcine coronary artery via elevating inosine 3',5'-cyclic monophosphate level. <b>2020</b> , 24, 14514-14524		4

80	Role of Phosphodiesterase in the Biology and Pathology of Diabetes. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	4
79	Phosphodiesterase Type 5 Inhibitors Synergize Vincristine in Killing Castration-Resistant Prostate Cancer Through Amplifying Mitotic Arrest Signaling. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1274	5.3	7
78	Associated Targets of the Antioxidant Cardioprotection of in Diabetic Cardiomyopathy by Using Open Targets Platform: A Systematic Review. <b>2020</b> , 2020, 7136075		10
77	Sildenafil Potentiates the Therapeutic Efficacy of Docetaxel in Advanced Prostate Cancer by Stimulating NO-cGMP Signaling. <b>2020</b> , 26, 5720-5734		15
76	Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: A Clinical and Translational Issue. <b>2020</b> , 2020, 7078108		4
75	Ruthenium-Catalyzed C <sub>H</sub> Activations for the Synthesis of Indole Derivatives. <b>2020</b> , 10, 1253		10
74	Extending the use of tadalafil scaffold: Development of novel selective phosphodiesterase 5 inhibitors and histone deacetylase inhibitors. <b>2020</b> , 98, 103742		9
73	Therapeutic approaches to diabetic cardiomyopathy: Targeting the antioxidant pathway. <b>2020</b> , 150, 106454		4
72	Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients. <b>2020</b> , 1874, 188383		9
71	PDE4 subtypes in cancer. <b>2020</b> , 39, 3791-3802		20
70	Radiosynthesis of a carbon-11 labeled PDE5 inhibitor [C]TPN171 as a new potential PET heart imaging agent. <b>2020</b> , 162, 109190		2
69	Myocardial ischaemia reperfusion injury and cardioprotection in the presence of sensory neuropathy: Therapeutic options. <i>British Journal of Pharmacology</i> , <b>2020</b> , 177, 5336-5356	8.6	6
68	Identification and experimental confirmation of novel cGMP efflux inhibitors by virtual ligand screening of vardenafil-analogues. <i>Biomedicine and Pharmacotherapy</i> , <b>2020</b> , 126, 110109	7.5	6
67	Enhanced nanoparticle accumulation by tumor-acidity-activatable release of sildenafil to induce vasodilation. <i>Biomaterials Science</i> , <b>2020</b> , 8, 3052-3062	7.4	10
66	Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy. <i>Journal of Medicinal Chemistry</i> , <b>2020</b> , 63, 8977-9002	8.3	41
65	Chlorogenic Acid Alleviates Hyperglycemia-Induced Cardiac Fibrosis through Activation of the NO/cGMP/PKG Pathway in Cardiac Fibroblasts. <i>Molecular Nutrition and Food Research</i> , <b>2021</b> , 65, e2000810	5.9	9
64	Repurposing of Phosphodiesterase-5 Inhibitors as Therapeutic Agents Against Human Gastric Cancer. <i>SSRN Electronic Journal</i> ,	1	
63	Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics. <i>Vaccines</i> , <b>2021</b> , 9,	5.3	19

62	Modulation of the Tumor Promoting Functions of Cancer Associated Fibroblasts by Phosphodiesterase Type 5 Inhibition Increases the Efficacy of Chemotherapy in Human Preclinical Models of Esophageal Adenocarcinoma. <i>SSRN Electronic Journal</i> ,	1	
61	New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 627229	5.3	7
60	Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 Inhibition. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3
59	Reno-protective effects of Phosphodiesterase 5 inhibitors. <i>Clinical and Experimental Nephrology</i> , <b>2021</b> , 25, 585-597	2.5	3
58	MTORC1-Regulated Metabolism Controlled by TSC2 Limits Cardiac Reperfusion Injury. <i>Circulation Research</i> , <b>2021</b> , 128, 639-651	15.7	3
57	Clinical and hemodynamic effects of oral sildenafil on biventricular function on patients with left ventricular systolic dysfunction. <i>International Journal of Clinical Practice</i> , <b>2021</b> , 75, e14171	2.9	0
56	Repurposing of sildenafil as antitumour; induction of cyclic guanosine monophosphate/protein kinase G pathway, caspase-dependent apoptosis and pivotal reduction of Nuclear factor kappa light chain enhancer of activated B cells in lung cancer. <i>Journal of Pharmacy and Pharmacology</i> , <b>2021</b> , 73, 1080-1091	4.8	1
55	Drug Discovery in Erectile Dysfunction and Sleep Disorders. 1-19		
54	Influence of cardiometabolic comorbidities on myocardial function, infarction, and cardioprotection: Role of cardiac redox signaling. <i>Free Radical Biology and Medicine</i> , <b>2021</b> , 166, 33-52	7.8	9
53	Sildenafil in Combination Therapy against Cancer: A Literature Review. <i>Current Medicinal Chemistry</i> , <b>2021</b> , 28, 2248-2259	4.3	3
52	Metabolism and Chronic Inflammation: The Links Between Chronic Heart Failure and Comorbidities. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 650278	5.4	6
51	Therapeutic potential of phosphodiesterase inhibitors in the treatment of osteoporosis: Scopes for therapeutic repurposing and discovery of new oral osteoanabolic drugs. <i>European Journal of Pharmacology</i> , <b>2021</b> , 899, 174015	5.3	2
50	Sildenafil in ophthalmology: An update. <i>Survey of Ophthalmology</i> , <b>2021</b> ,	6.1	3
49	Mechanism of rutaecarpine on ethanol-induced acute gastric ulcer using integrated metabolomics and network pharmacology. <i>Biomedicine and Pharmacotherapy</i> , <b>2021</b> , 138, 111490	7.5	2
48	Impacts of caffeine on resistant chicken performance and cardiovascular gene expression. <i>Journal of Animal Physiology and Animal Nutrition</i> , <b>2021</b> ,	2.6	
47	Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities. <i>Pharmacology &amp; Therapeutics</i> , <b>2021</b> , 226, 107858	13.9	2
46	Phosphodiesterase-1 inhibitor modulates Ca regulation in sirtuin 1-deficient mouse cardiomyocytes. <i>European Journal of Pharmacology</i> , <b>2021</b> , 910, 174498	5.3	
45	Leucine and Sildenafil Combination Therapy Reduces Body Weight and Metformin Enhances the Effect at Low Dose: A Randomized Controlled Trial. <i>American Journal of Therapeutics</i> , <b>2021</b> , 28, e1-e13	1	2



44	Cyclic Nucleotide Phosphodiesterases and Compartmentation in Normal and Diseased Heart. <i>Cardiac and Vascular Biology</i> , <b>2017</b> , 97-116	0.2	1
43	Modulation of the tumour promoting functions of cancer associated fibroblasts by phosphodiesterase type 5 inhibition increases the efficacy of chemotherapy in human preclinical models of esophageal adenocarcinoma.		2
42	Impact of Mitochondrial Ca <sup>2+</sup> -Sensitive Potassium (mBKCa) Channels in Sildenafil-Induced Cardioprotection in Rats. <i>PLoS ONE</i> , <b>2015</b> , 10, e0144737	3.7	34
41	Tadalafil inhibits elevated glutamic oxaloacetic transaminase during alcohol aflatoxin induced hepatocellular carcinoma in rats. <i>International Journal of Immunotherapy and Cancer Research</i> , <b>2020</b> , 6, 010-013	0.3	3
40	PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide. <i>Oncotarget</i> , <b>2017</b> , 8, 1449-1468	3.3	37
39	PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]. <i>Oncotarget</i> , <b>2017</b> , 8, 13464-13475	3.3	9
38	Curcumin interacts with sildenafil to kill GI tumor cells via endoplasmic reticulum stress and reactive oxygen/ nitrogen species. <i>Oncotarget</i> , <b>2017</b> , 8, 99451-99469	3.3	17
37	Integration of Transcriptomics and Metabolomics to Reveal the Molecular Mechanisms Underlying Rhodium Nanoparticles-Based Photodynamic Cancer Therapy. <i>Pharmaceutics</i> , <b>2021</b> , 13,	6.4	3
36	The Involvement of CXC Motif Chemokine Ligand 10 (CXCL10) and Its Related Chemokines in the Pathogenesis of Coronary Artery Disease and in the COVID-19 Vaccination: A Narrative Review. <i>Vaccines</i> , <b>2021</b> , 9,	5.3	1
35	Therapeutic Values of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma: Facts and Hopes. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
34	An Updated Insight Into Molecular Mechanism of Hydrogen Sulfide in Cardiomyopathy and Myocardial Ischemia/Reperfusion Injury Under Diabetes. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 651884	5.6	2
33	Let's rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomy. <i>Journal of Exercise Rehabilitation</i> , <b>2016</b> , 12, 143-7	1.8	
32	cGMP Phosphodiesterases (cGMP PDEs) As Therapeutic Targets in Cancer. <i>Gene, Cell and Tissue</i> , <b>2017</b> , 4,	0.6	
31	Non-classical effects of sildenafil in clinical medicine: an interdisciplinary approach. <i>Meditinskiy Sovet</i> , <b>2019</b> , 192-202	0.4	
30	Activation of the cGMP/protein kinase G system in breast cancer by the dopamine receptor-1.. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , <b>2019</b> , 2, 933-947	4.5	0
29	Combination of the Phosphodiesterase Inhibitors Sildenafil and Milrinone Induces Cardioprotection With Various Conditioning Strategies. <i>Journal of Cardiovascular Pharmacology</i> , <b>2020</b> , 76, 684-691	3.1	0
28	NO-HDAC dual inhibitors. <i>European Journal of Medicinal Chemistry</i> , <b>2022</b> , 227, 113934	6.8	1
27	First molecular modelling report on tri-substituted pyrazolines as phosphodiesterase 5 (PDE5) inhibitors through classical and machine learning based multi-QSAR analysis. <i>SAR and QSAR in Environmental Research</i> , <b>2021</b> , 32, 917-939	3.5	1

26	Hydroalcoholic Extract of <i>Levisticum officinale</i> Increases cGMP Signaling Pathway by Down-Regulating PDE5 Expression and Induction of Apoptosis in MCF-7 and MDA-MB-468 Breast Cancer Cell Lines. <i>Iranian Biomedical Journal</i> , <b>2019</b> , 23, 280-6	2	2
25	Efeito cardioprotetor dos inibidores da Fosfodiesterase 5 em modelo de Diabetes Mellitus experimental. <i>ABCS Health Sciences</i> ,	0.6	
24	Does treatment of erectile dysfunction with PDE 5 inhibitor Tadalafil improve quality of life in male patients with compensated chronic liver disease? A prospective pilot study. <i>Journal of Clinical and Experimental Hepatology</i> , <b>2022</b> ,	4.1	0
23	Cardiomyocyte Atrophy, an Underestimated Contributor in Doxorubicin-Induced Cardiotoxicity.. <i>Frontiers in Cardiovascular Medicine</i> , <b>2022</b> , 9, 812578	5.4	2
22	Sildenafil prevents right ventricular hypertrophy and improves heart rate variability in rats with pulmonary hypertension secondary to experimental diabetes.. <i>Clinical and Experimental Hypertension</i> , <b>2022</b> , 1-11	2.2	
21	Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	0
20	Tadalafil in Increasing Doses: The Influence on Coronary Blood Flow and Oxidative Stress in Isolated Rat Hearts.. <i>Pharmacology</i> , <b>2021</b> , 1-10	2.3	1
19	Image_1.TIF. <b>2020</b> ,		
18	Image_2.TIF. <b>2020</b> ,		
17	Image_3.TIF. <b>2020</b> ,		
16	Image_4.TIF. <b>2020</b> ,		
15	Presentation_1.PPTX. <b>2019</b> ,		
14	Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts. <i>Cell Reports Medicine</i> , <b>2022</b> , 3, 100541	18	0
13	A Novel Sulindac Derivative Protects against Oxidative Damage by a Cyclooxygenase-Independent Mechanism. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2022</b> , 382, 79-87	4.7	
12	Cilostazol treatment for preventing adverse cardiovascular events in patients with type 2 diabetes and coronary atherosclerosis: Long-term follow-up of the ESCAPE study.		
11	Potential diabetic cardiomyopathy therapies targeting pyroptosis: A mini review. 9,		0
10	Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer. <b>2022</b> , 64, 100865		0
9	Nrf2 transcriptional upregulation of IDH2 to tune mitochondrial dynamics and rescue angiogenic function of diabetic EPCs. <b>2022</b> , 56, 102449		0

8	Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine: a possible prevention strategy for COVID-19?.	0
7	Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders. <b>2023</b> , 63,	1
6	Chronic liver diseases and erectile dysfunction. 10,	0
5	Heterogeneity of cGMP signalling in tumour cells and the tumour microenvironment: Challenges and chances for cancer pharmacology and therapeutics. <b>2023</b> , 242, 108337	0
4	Inhibition of phosphodiesterase 5A by tadalafil improves SIRT1 expression and activity in insulin-resistant podocytes. <b>2023</b> , 105, 110622	0
3	Combined systematic pharmacology and urine metabonomics to study the therapeutic mechanism of type 2 diabetic treated with the herbal pair of <i>Salvia miltiorrhiza</i> Bunge and <i>Pueraria montana</i> var. <i>lobata</i> (Willd.) Sanjappa & Pradeep. <b>2023</b> , 1217, 123627	0
2	Changes in Left Ventricular Ejection Fraction and Oxidative Stress after Phosphodiesterase Type-5 Inhibitor Treatment in an Experimental Model of Retrograde Rat Perfusion. <b>2023</b> , 59, 458	0
1	Androgen-deprivation therapy with leuprolide increases abdominal adiposity without causing cardiac dysfunction in middle-aged male mice: effect of sildenafil. <b>2023</b> , 324, R589-R600	1